We collected Daunorubicin HCl from 182 normolipidemic individuals defined as the 5th–95th percentile for TC, TG, HDLC, and LDLC, adjusted for age and sex [20], and determined their level of plasma PCSK9. Fig. 2 is a histogram of the distribution of plasma PCSK9 levels while the inset shows the determination of its concentration for one individual. Table 1 gives the means ± SD for age, body mass index (BMI), lipid, and plasma PCSK9 measurements of all participants, and gender sub-categories. Neither plasma PCSK9 nor TC was significantly different between men and women. TG and HDLC means were significantly higher and lower, respectively for our male versus female participants, a documented trend [21]. Male (n = 9 cool plasma PCSK9 levels ranged from 0.56 to 13.39 μg/ml with a mean of 6.08 ± 1.96 μg/ml and female (n = 84) plasma PCSK9 levels ranged from 0.42 to 12.33 μg/ml with a mean of 6.46 ± 1.99 μg/ml. For all 182 participants Spearman analysis showed no correlation between PCSK9 and lipoprotein parameters ( Table 2). Analyses of gender sub-categories showed a positive correlation between PCSK9 and TC (r = 0.276, p = 0.006), LDLC (r = 0.282, p = 0.005), and TC/HDLC (r = 0.228, p = 0.024) in men ( Table 2 and Fig. 3A–C, respectively) while no such correlation was observed in women ( Table 2 and Fig. 3D–F).